CELCUITY INC. (CELC) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 142.96M USD | Research and Development Expense |
| Revenue | (m) | |
| Stock-based compensation | 28.46M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -208.68M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $142.96M | (m) | $28.46M | $-208.68M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $148.30M | (m) | $24.26M | $-186.57M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $145.00M | (m) | $21.38M | $-172.19M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $140.84M | (m) | $14.24M | $-159.42M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $133.51M | (m) | $9.39M | $-146.63M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $115.78M | (m) | $8.10M | $-126.91M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $104.20M | (m) | $6.99M | $-113.27M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $88.81M | (m) | $5.92M | $-96.57M | $8.40M | (m) | (m) | -11.49× | Reported |
| 2024-06-30 | $78.71M | (m) | $5.09M | $-85.40M | $6.43M | (m) | (m) | -13.28× | Reported |
| 2024-03-31 | $69.96M | (m) | $4.96M | $-76.18M | $5.49M | (m) | (m) | -13.89× | Reported |
| 2023-12-31 | $60.59M | (m) | $4.90M | $-66.23M | $5.33M | (m) | (m) | -12.43× | Reported |
| 2023-09-30 | $53.12M | (m) | $4.80M | $-58.14M | $4.61M | (m) | (m) | -12.62× | Reported |
| 2023-06-30 | $45.25M | (m) | $4.91M | $-49.89M | $3.77M | (m) | (m) | -13.22× | Reported |
| 2023-03-31 | $39.87M | (m) | $5.16M | $-44.43M | $2.91M | (m) | (m) | -15.25× | Reported |
| 2022-12-31 | $35.29M | (m) | $4.64M | $-39.39M | $2.11M | (m) | (m) | -18.70× | Reported |
| 2022-09-30 | $30.18M | (m) | $4.42M | $-34.07M | $1.87M | (m) | (m) | -18.26× | Reported |
| 2022-06-30 | $25.52M | (m) | $3.90M | $-29.03M | $1.76M | (m) | (m) | -16.48× | Reported |
| 2022-03-31 | $30.22M | (m) | $2.92M | $-33.07M | $1.70M | (m) | (m) | -19.48× | Reported |
| 2021-12-31 | $25.76M | (m) | $2.61M | $-28.36M | $1.26M | (m) | (m) | -22.46× | Reported |
| 2021-09-30 | $22.37M | (m) | $2.12M | $-24.59M | $824.31K | (m) | (m) | -29.83× | Reported |
| 2021-06-30 | $19.38M | (m) | $1.87M | $-21.47M | $391.27K | (m) | (m) | -54.86× | Reported |
| 2021-03-31 | $8.07M | (m) | $1.75M | $-10.04M | $111.00 | (m) | (m) | -90424.51× | Reported |
| 2020-12-31 | $7.68M | (m) | $1.76M | $-9.56M | $120.00 | (m) | (m) | -79634.70× | Reported |
| 2020-09-30 | $7.07M | (m) | $1.70M | $-8.90M | $129.00 | (m) | (m) | -69012.34× | Reported |
| 2020-06-30 | $6.82M | (m) | $1.55M | $-8.51M | $138.00 | (m) | (m) | -61694.44× | Reported |
| 2020-03-31 | $6.53M | (m) | $1.32M | $-8.14M | $149.00 | (m) | (m) | -54641.68× | Reported |
| 2019-12-31 | $6.27M | (m) | $1.04M | $-7.81M | $159.00 | (m) | (m) | -49089.94× | Reported |
| 2019-09-30 | $6.41M | (m) | $935.71K | $-7.86M | $169.00 | (m) | (m) | -46501.44× | Reported |
| 2019-06-30 | $6.29M | (m) | $932.74K | $-7.74M | $196.00 | (m) | (m) | -39506.47× | Reported |
| 2019-03-31 | $6.37M | (m) | $1.02M | $-7.83M | $154.00 | (m) | (m) | -50848.92× | Reported |
| 2018-12-31 | $6.33M | (m) | $1.17M | $-7.93M | $111.00 | (m) | (m) | -71464.31× | Reported |
| 2018-09-30 | $6.09M | (m) | $1.23M | $-7.81M | $65.00 | (m) | (m) | -120082.54× | Reported |
| 2018-06-30 | $5.86M | (m) | $1.06M | $-7.36M | $264.98K | (m) | (m) | -27.77× | Reported |
| 2018-03-31 | $5.62M | (m) | $1.11M | $-7.04M | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $4.98M | (m) | $874.39K | $-5.95M | $451.66K | (m) | (m) | -13.18× | Reported |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $3.06M | (m) | $187.31K | $-3.33M | $0.00 | (m) | (m) | (m) | Reported |
| 2016-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERACYTE, INC. (VCYT) | United States | $3.904B | 41.21 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| GRAIL, Inc. (GRAL) | United States | $5.591B | -7.78 |
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| BIODESIX INC (BDSX) | United States | $0.312B |